Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces that Chris Lea, Group Finance Director of the Company, will be stepping down as
Omega Diagnostics Gp (AIM:ODX) Trading update
Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, provides a trading update which reflects lower than expected revenue,
Omega Diagnostics Gp (AIM:ODX) US expansion update
Maiden US Laboratory FoodPrint® installation,
Omega Diagnostics Gp (AIM:ODX) Positive WHO data received for VISITECT® CD4 test
Test shows high diagnostic accuracy (specificity and sensitivity)
Omega Diagnostics Gp (AIM:ODX) Change of preliminary results date
Change of preliminary results date and investor presentation and update to CD4 sale
Omega Diagnostics Gp (AIM:ODX) Completion of Sale of the CD4 Business
Completion of Sale of the CD4 Business
Omega Diagnostics Heads of Terms agreed for Sale of CD4 Busines
Omega Diagnostics Group PLC, (AIM: ODX). announced that it has selected a preferred bidder for its CD4 business after having made an announcement nearly two months back.
Omega Diagnostics Gp (AIM:ODX) Result of Open Offer
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces the results of its Open Offer.
Omega Diagnostics Gp (AIM:ODX) Placing, Subscription and Open Offer
Placing of 50,000,000 New Ordinary Shares and Warrants
Omega Diagnostics Gp (AIM:ODX) Trading Update
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, provides the following trading update for the year ended
Omega Diagnostics Gp (AIM:ODX) Result of Open Offer
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, today announces the results of its Open Offer.